Mustang Bio Inc (MBIO) has released an update.
Mustang Bio, Inc. is in the process of selling its cell processing facility in Massachusetts to uBriGene, a subsidiary of a Chinese organization. The deal, which is not conditioned on U.S. foreign investment approval, has undergone multiple extended reviews by the Committee on Foreign Investment in the United States (CFIUS) due to national security considerations. To date, CFIUS has twice requested more time for assessment, initiating a second review period set to conclude by March 28, 2024, with the possibility of a further 45-day investigation if needed.
For further insights into MBIO stock, check out TipRanks’ Stock Analysis page.
